American Capital Management Inc. raised its stake in Icon Plc (NASDAQ:ICLR) by 0.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 832,990 shares of the medical research company’s stock after buying an additional 1,000 shares during the period. Icon Plc accounts for about 5.2% of American Capital Management Inc.’s investment portfolio, making the stock its 3rd largest position. American Capital Management Inc. owned about 1.55% of Icon Plc worth $81,458,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. US Bancorp DE raised its position in shares of Icon Plc by 15.0% in the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock valued at $154,000 after buying an additional 251 shares during the last quarter. Huntington National Bank raised its stake in Icon Plc by 5.0% in the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after buying an additional 77 shares in the last quarter. Quantbot Technologies LP raised its stake in Icon Plc by 40.9% in the first quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock worth $161,000 after buying an additional 587 shares in the last quarter. IFP Advisors Inc raised its stake in Icon Plc by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock worth $178,000 after buying an additional 59 shares in the last quarter. Finally, Atria Investments LLC purchased a new stake in Icon Plc during the first quarter worth $214,000. Institutional investors own 91.65% of the company’s stock.
Shares of Icon Plc (NASDAQ ICLR) opened at 104.99 on Friday. The stock’s 50 day moving average is $101.46 and its 200-day moving average is $89.84. Icon Plc has a 52 week low of $73.76 and a 52 week high of $109.32. The stock has a market capitalization of $5.67 billion, a price-to-earnings ratio of 21.30 and a beta of 0.60.
Icon Plc (NASDAQ:ICLR) last announced its earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.01. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The company had revenue of $431 million during the quarter, compared to analysts’ expectations of $430.68 million. During the same period last year, the business posted $1.14 EPS. Icon Plc’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, analysts anticipate that Icon Plc will post $5.32 earnings per share for the current fiscal year.
A number of analysts have weighed in on the stock. Zacks Investment Research lowered shares of Icon Plc from a “buy” rating to a “hold” rating in a research note on Friday. KeyCorp reissued an “overweight” rating on shares of Icon Plc in a report on Monday, July 31st. SunTrust Banks, Inc. raised shares of Icon Plc from a “hold” rating to a “buy” rating and raised their price objective for the stock from $93.00 to $126.00 in a report on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating on shares of Icon Plc in a report on Sunday, July 30th. Finally, Credit Suisse Group reissued a “buy” rating on shares of Icon Plc in a report on Friday, July 28th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $108.38.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
What are top analysts saying about Icon Plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Icon Plc and related companies.